Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Foghorn Therapeutics Inc. - Common Stock (NQ:FHTX)

2.245 -0.675 (-23.12%)
Delayed Quote Updated: 12:37 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Foghorn Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics Announces FDA Has Lifted Clinical Hold on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML/MDS Patients
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics Provides First Quarter 2023 Financial and Corporate Update
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Analyst Expectations for Foghorn Therapeutics's Future ↗
 
Via Benzinga
News headline image
Expert Ratings for Foghorn Therapeutics ↗
 
Via Benzinga
News headline image
Foghorn Therapeutics Earnings Perspective: Return On Capital Employed ↗
 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
  Thursday saw 177 companies set new 52-week lows. 
Via Benzinga
News headline image
Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Investor Conference
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Crude Oil Up 1.5%; Philips Shares Jump After Q1 Results ↗
U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite dropping around 40 points on Monday. The Dow traded up 0.05% to 33,827.42 while the NASDAQ fell 0.33% to 12,032.16.... 
Via Benzinga
News headline image
Why IDEAYA Biosciences Shares Are Trading Higher By Around 27%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers Aclarion, Inc. (NASDAQ: ACON) shares surged 152% to $1.85 amid the publication of durability data for the company's back pain treatment. 
Via Benzinga
News headline image
US Stocks Turn Lower; Nasdaq Dips 100 Points ↗
U.S. stocks turned lower midway through trading, with the Nasdaq Composite dropping around 100 points on Monday. The Dow traded down 0.19% to 33,744.92 while the NASDAQ fell 0.84% to 11,971. The S&P... 
Via Benzinga
News headline image
More Trouble For Foghorn Therapeutics: After Blood Cancer Trial, FDA Puts Another Cancer Trial On Clinical Hold ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Foghorn Therapeutics Provides an Update on FHD-609
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics to Present Preclinical Data from Its Selective CBP and EP300 Protein Degrader Programs and Preclinical Data for FHD-286, a Potent, Selective Inhibitor of BRG1 and BRM, at the 2023 American Association for Cancer Research Annual
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics to Highlight Transcription Factor and Protein Degradation Capabilities at the 18th Annual Drug Discovery Chemistry Meeting
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 28, 2023 ↗
 
Via Benzinga
News headline image
Foghorn Therapeutics Provides 2023 Outlook and Full Year 2022 Corporate Update
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics to Participate at Cowen’s 43rd Annual Health Care Conference
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Altimmune, Foghorn Therapeutics, and Precigen Shares Crashed This Week ↗
Concerns about a tough financing environment weighed on clinical-stage biotech stocks this week. 
Via The Motley Fool
News headline image
Foghorn Therapeutics Highlights Recent Clinical and Research Progress and Provides Strategic Objectives for 2023
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023 ↗
 
Via Benzinga
News headline image
Foghorn Therapeutics Announces New Preclinical Data for FHD-286 in AML to Be Presented at the American Society of Hematology Annual Meeting
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
  During Wednesday's session, 107 stocks hit new 52-week lows. 
Via Benzinga
News headline image
Foghorn Therapeutics to Participate at the Evercore ISI HealthCONx Conference
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics to Present at Connective Tissue Oncology Society Annual Meeting
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics to Present New Preclinical Data for BRG1/BRM Inhibitor FHD-286 in Combination with Anti-PD-1 Antibody at Society for Immunotherapy of Cancer 37th Annual Meeting
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics Provides Third Quarter 2022 Financial and Corporate Update
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics Appoints Dr. Thomas J. Lynch, Jr. to Its Board of Directors
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
News headline image
Foghorn Therapeutics Announces New Data Demonstrating BRD9 Degradation in Patient Tumor Biopsies and Discloses New Selective CBP Program
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.